Welcome to KineMed | The Disease Pathway Experts | Unparalleled insights into disease pathways | KineMed is a field-leading US biotech company that serves major pharmaceutical clients by making predictions of efficacy and toxicity to accelerate and reduce the cost of drug development. KineMed’s unique, patented isotopic tracer technology enables our clients to track key chemical pathways within living systems. Combined with deep expertise, we offer unparalleled insight into the complex biological processes underlying the root causes of disease.
KineMed, pharma biotech, therapeutic efficacy, drug discovery, drug development, pathways in disease, pharma research and development, alzheimer disease, parkinson disease, toxicity, isotopic tracer, causes of disease, blockbuster drugs, mass spectroscopy, therapeutics, metabolic disease, diabetes, fibrotics, idiopathic pulmonary fibrosis, disease processes, drug candidates, stable isotope tracers, isotope, Systems Biology, Cellular Proteomics, Disease Pathway, Dynamic Proteomics, Network Dynamics
Copyright (c) 2011 KineMed, Inc. | All Rights ReservedTerms_%26_Conditions.htmlshapeimage_2_link_0

 About Us   |   Our Team   |  Our Services   |   Key Technologies   |  Therapeutic Focus   |   Contact Us

Privacy | Terms & Conditions Privacy.htmlTerms_%26_Conditions.htmlshapeimage_3_link_0shapeimage_3_link_1

5980 Horton Street | Suite 470 | Emeryville, CA 94608 | Tel.: USA [1] 510.655.6525 | Fax: [1] 510.655.6506 | TOLL-FREE: 855.KINEMED | E-mail: info@kinemed.com

  Press Room   |   For Investors   |   Careers at KineMed   |   Partner Login

Latest News  |  KineMed announces research collaboration with Pfizer   ‣‣

Find out more about KineMed’s world-leading drug development technologies ‣‣

CUSTOMER SERVICES DIAL USA [1] 510.655.6525 | TOLL-FREE  855.KINEMED

Technology Highlight
Featured Disease Research Programs
Alzheimers’ & Parkinson’s Disease
Diabetes
Idiopathic Pulmonary Fibrosis
Cardiovascular

May 15, 2012

KineMed to discuss New Applications of Biomarkers for Neurodegenerative Therapeutics at the 7th Annual Neurotech Investing & Partnering Conference

Read More ‣‣

May 14, 2012

KineMed and CHDI Foundation collaborate to develop new biomarkers of disease progression and to evaluate potential therapeutics for Huntington’s disease

Read More ‣‣

Apr 10, 2012

Novel atherosclerosis-reversing, heart disease therapy wins NIH clinical development grant

Read More ‣‣

Dynamic Proteomics
Press ReleasesTherapeutic_Focus___Cardiovascular.htmlTherapeutic_Focus___Cardiovascular.htmlshapeimage_16_link_0
Press ReleasesTherapeutic_Focus___Fibrotics.htmlTherapeutic_Focus___Fibrotics.htmlshapeimage_17_link_0
Press ReleasesTherapeutic_Focus___Neuro.htmlTherapeutic_Focus___Neuro.htmlshapeimage_18_link_0
Find out more ‣‣ Therapeutic_Focus___Metabolic.htmlTherapeutic_Focus___Metabolic.htmlshapeimage_19_link_0
Find out more ‣‣

Dr. Marc Hellerstein  |  Chair, Scientific Advisory Board

Proteome Dynamics and Metabolic Flux Microscopy

Personalized Medicine World Conference 2012

Watch Video ‣‣

 

Upcoming |  Join David Fineman, CEO at Neurotech Investing & Partnering | May 21, 2012 ‣‣